阿托伐他汀钙联合依折麦布治疗冠心病的效果及安全性分析  

Efficacy and safety analysis of atorvastatin calcium combined with ezetimibe in the treatment of coronary heart disease

作　　者：李玲 卢波 冯玲玲 LI Ling;LU Bo;FENG Ling-ling(Mengyin County People's Hospital,Linyi 276200,China)

机构地区：[1]蒙阴县人民医院,276200

出　　处：《中国现代药物应用》2024年第10期102-105,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析冠心病临床治疗过程中采用阿托伐他汀钙、依折麦布共同治疗的效果、安全性。方法76例冠心病患者,按治疗方式不同分为研究组和对照组,各38例。对照组单独使用阿托伐他汀钙治疗,研究组使用阿托伐他汀钙与依折麦布联合治疗。比较两组的治疗效果,治疗前后的血脂指标[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C)]水平,不良反应发生情况,治疗前后的氧化应激指标[丙二醇(MDA)、超氧化物歧化酶(SOD)、髓过氧化物酶(MPO)]水平。结果治疗后,研究组总有效率94.74%显著高于对照组的76.32%(P<0.05)。治疗后,两组的TC、LDL-C、TG水平均低于治疗前,HDL-C水平高于治疗前,且研究组的TC(2.15±0.33)mmol/L、LDL-C(1.46±0.29)mmol/L、TG(1.12±0.05)mmol/L均低于对照组的(3.72±0.26)、(2.07±0.31)、(1.48±0.04)mmol/L,HDL-C(1.43±0.06)mmol/L高于对照组的(1.18±0.05)mmol/L,差异有统计学意义(P<0.05)。研究组不良反应发生率相比对照组略低,但差异无统计学意义(P>0.05)。治疗后,两组的SOD高于治疗前,MDA、MPO低于治疗前,且研究组的SOD(323.38±40.57)U/L高于对照组的(297.96±39.65)U/L,MDA(4.67±0.48)μmol/L、MPO(93.82±1.01)ng/ml低于对照组的(6.45±0.69)μmol/L、(95.57±1.38)ng/ml,差异有统计学意义(P<0.05)。结论冠心病临床治疗过程中采用阿托伐他汀钙、依折麦布共同治疗具有更加明显的疗效,患者联合用药之后并不会有严重的不良反应产生,具有较高的安全性。Objective To analyze the effect and safety of atorvastatin calcium combined with ezetimibe in the treatment of coronary heart disease.Methods 76 patients with coronary heart disease were divided into a study group and a control group according to different treatment methods,each with 38 cases.The control group was treated with atorvastatin calcium alone,and the study group was treated with atorvastatin calcium combined with ezetimibe.Both groups were compared in terms of treatment effect,blood lipid indexes[total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-C)]before and after treatment,and the occurrence of adverse reactions,levels of oxidative stress indexes[malondialdehyde(MDA),superoxide dismutase(SOD),myeloperoxidase(MPO)]before and after treatment.Results After treatment,the total effective rate of the study group was 94.74%,which was significantly higher than the control group's 76.32%(P<0.05).After treatment,the levels of TC,LDL-C and TG in both groups were lower than those before treatment,and the level of HDL-C was higher than that before treatment;the study group had TC of(2.15±0.33)mmol/L,LDL-C of(1.46±0.29)mmol/L and TG of(1.12±0.05)mmol/L,which were lower than(3.72±0.26),(2.07±0.31)and(1.48±0.04)mmol/L in the control group;the study group had higher HDL-C of(1.43±0.06)mmol/L than(1.18±0.05)mmol/L in the control group;the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was a little lower than that in the control group,but the difference was not statistically significant(P>0.05).After treatment,SOD in both groups was higher than that before treatment,and MDA and MPO were lower than those before treatment;the study group had higher SOD of(323.38±40.57)U/L than(297.96±39.65)U/L in the control group;the study group had MDA of(4.67±0.48)μmol/L and MPO of(93.82±1.01)ng/ml,which were lower than(6.45±0.69)μmol/L and(95.57±1.38)ng/ml in the control group;the differe

关 键 词：冠心病 阿托伐他汀钙 依折麦布 治疗效果 不良反应 

分 类 号：R541.4[医药卫生—心血管疾病]